Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023

Affiliations

• ¹ Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Kanazawa Ward, Yokohama, Kanagawa, Japan.
• ² Graduate School of Medicine, Kyoto University, Kyoto, Japan.
• ³ Value, Evidence and Access Department, IMAT, Janssen Pharmaceutical K.K., Tokyo, Japan.
• ⁴ Policy Department, IMAT, Janssen Pharmaceutical K.K., Tokyo, Japan.
• ⁵ Asia Pacific Regional Market Access, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore, Singapore.
• ⁶ Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
• ⁷ Johnson and Johnson Global Commercial Strategy Organization, Beerse, Belgium.
• ⁸ Ottawa Hospital Research Institute, Ottawa, Canada.
• ⁹ EVERSANA™, Burlington, ON, Canada.
• ¹⁰ EVERSANA™, Burlington, ON, Canada. [email protected].